{
  "eval_id": "S03",
  "eval_file": "evals/single/S03.json",
  "timestamp": "2025-09-18T16:39:25.254104Z",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "For a patient with HR+/HER2- breast cancer who progressed after CDK4/6 inhibition, the next steps depend on previous endocrine therapy, performance status, and presence of visceral disease. Any treatment discussion should be grounded in the EMA label and current guidelines—please send the SmPC for the product you’re referencing, and highlight any specific label sections you want to discuss."
}